17.5% Weight Reduction with Retatrutide

In the Phase 2 clinical trial of Retatrutide at Lilly, the Retatrutide showed significant weight loss effects, with an average weight loss of 17.5% within 24 weeks. This study drug has unique characteristics in targeting GIP, GLP-1, and glucagon receptors, which is a novel approach compared to existing obesity treatment methods. According to the New England Journal of Medicine, the study changed the dosage and indicated that the maximum dose resulted in the greatest weight loss.

Researchers recruited 338 adults with a BMI exceeding 30 or a BMI 27-30 and one or more weight related diseases, and were assigned to one of the following experimental groups or a placebo group:

1 mg subcutaneous injection of Retatrutide

Subcutaneous injection of 4 mg of Retatrutide with an beginning dose of 2 mg

Subcutaneous injection of 4 mg of Retatrutide with an beginning dose of 4 mg

Subcutaneous injection of 8 mg of Retatrutide with an beginning dose of 2 mg

Subcutaneous injection of 8 mg of Retatrutide with an beginning dose of 4 mg

Subcutaneous injection of 12 mg of Retatrutide with an beginning dose of 2 mg

The promising results of this experiment have paved the way for further phase III studies to evaluate the efficacy of Retatrutide in comprehensive obesity management and its impact on related health issues.